Pernix Therapeutics Holdings, Inc. (Pernix) currently holds the rights to all commercialization activities for TREXIMET® in the United States, with Aralez receiving certain royalties. Aralez holds the development and commercialization rights outside the United States, and may seek regulatory approval on the basis of the New Drug Applications (NDA) approved by the FDA for TREXIMET.
For more information about TREXIMET, please contact Pernix.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.